A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study

Table 3 Summary of pegloticase exposure with methotrexate co-treatment (current study) and as monotherapy (calculated using pharmacokinetic findings of prior phase 3 trials [23, 26])

	C_max (µg/mL)		C_min (µg/mL)
	Pegloticase + MTX	Pegloticase (monotherapy trial)	Pegloticase + MTX	Pegloticase (monotherapy trial)
Median (Q1, Q3)	2.11 (1.65, 2.59)	1.51 (BQL, 2.48)	1.03 (BQL, 1.23)	BQL (BQL, BQL)
BQL, n/N (%)	0/14 (0%)	25/85 (29%)	5/14 (36%)	63/82 (77%)

C_max Maximum pegloticase concentration during the treatment period, C_min Minimum pegloticase concentration during the treatment period, BQL Below quantitation limit (0.6 µg/mL), MTX Methotrexate

ISSN: 1478-6362